Novo Nordisk: Buy the Re-Rate as Wegovy Pill Rewrites Growth
Novo Nordisk’s Q1 beat and the blockbuster uptake of the Wegovy pill give the stock room to re-rate. With reported Q1 sales of $15.17B, guidance raised to $42.39-$46.24B, and more than 2 million Wegovy prescriptions since launch, the company is pivoting from price-driven headwinds to volume-led growth. Valuation (market cap ~$209B, P/E ~10.8) leave…